# Galanthamine

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/galanthamine
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** Galantamine, Galanthamine hydrobromide, Razadyne, Reminyl, Nivalin, (-)-Galanthamine, Snowdrop alkaloid, 4aS,6R,8aS-Galanthamine, Bulgarian snowdrop extract, Amaryllidaceae alkaloid

## Overview

Galanthamine is a tertiary alkaloid derived from plants such as Galanthus nivalis (snowdrop) and Narcissus species that acts as a reversible, competitive [acetylcholine](/ingredients/condition/cognitive)sterase inhibitor and allosteric potentiating ligand at nicotinic acetylcholine receptors. It is clinically approved for mild-to-moderate Alzheimer's disease, improving cognitive scores by 3–4 points on the ADAS-cog scale across multiple large randomized controlled trials.

## Health Benefits

• Improves [cognitive function](/ingredients/condition/cognitive) in mild-to-moderate Alzheimer's disease by 3-4 points on ADAS-cog scale (Strong evidence: multiple RCTs, n=636-2045)
• Enhances activities of daily living (ADL) and global function in dementia patients (Strong evidence: 24% less ADL decline in 2-year RCT)
• Reduces cognitive decline progression by 34% over 2 years compared to placebo (Strong evidence: PMID PMC3937252, n=2045)
• May reduce mortality in Alzheimer's patients - 3.1% vs 4.9% placebo (Moderate evidence: single large RCT terminated early for benefit)
• Maintains cognitive benefits in vascular dementia and AD with cerebrovascular disease (Moderate evidence: 6-month open-label extension, n=459)

## Mechanism of Action

Galanthamine reversibly inhibits [acetylcholine](/ingredients/condition/cognitive)sterase (AChE) at the synaptic cleft, preventing the breakdown of acetylcholine and increasing its availability at muscarinic and nicotinic receptors in cortical and hippocampal circuits. It simultaneously acts as an allosteric potentiating ligand (APL) at nicotinic acetylcholine receptors (nAChRs), specifically the α4β2 and α7 subtypes, sensitizing them to acetylcholine without directly activating them. This dual mechanism enhances cholinergic neurotransmission more robustly than AChE inhibition alone, potentially also promoting neuroprotection via α7 nAChR-mediated reduction of amyloid-beta toxicity.

## Clinical Summary

Multiple large randomized controlled trials (RCTs) with sample sizes ranging from 636 to 2,045 participants have demonstrated that galanthamine at 16–24 mg/day produces statistically significant improvements of 3–4 points on the ADAS-cog scale compared to placebo in patients with mild-to-moderate Alzheimer's disease. A 2-year RCT showed 24% less decline in activities of daily living (ADL) scores in the galanthamine group relative to placebo, indicating functional as well as [cognitive](/ingredients/condition/cognitive) benefit. Evidence for its cognitive effects is rated strong based on consistency across trials conducted by independent groups; evidence for slowing disease progression is more limited and requires further long-term study. Galanthamine has not demonstrated robust efficacy in vascular dementia or other non-Alzheimer's dementias in meta-analyses.

## Nutritional Profile

Galanthamine (C₁₇H₂₁NO₃, MW 287.35 g/mol) is a tertiary alkaloid, not a nutritional supplement, and therefore lacks a conventional nutritional profile of macronutrients, vitamins, minerals, fiber, or protein. Key pharmacological and biochemical details: • Bioactive compound: Galanthamine itself is the sole active pharmacological agent — a selective, competitive, and reversible [acetylcholine](/ingredients/condition/cognitive)sterase (AChE) inhibitor (IC₅₀ ~0.35–0.50 µM) and an allosteric potentiating ligand (APL) at nicotinic acetylcholine receptors (nAChRs), particularly α7 subtype. • Natural source concentrations: Found in Amaryllidaceae plants — Galanthus nivalis (snowdrop) bulbs contain approximately 0.05–0.1% w/w galanthamine; Narcissus pseudonarcissus (daffodil) bulbs ~0.01–0.05% w/w; Leucojum aestivum (summer snowflake) bulbs ~0.1–0.2% w/w, which is the primary commercial botanical source. Lycoris radiata also contains trace amounts (~0.01%). • Pharmaceutical dosing: Typical therapeutic doses are 16–24 mg/day (given as 8–12 mg twice daily in immediate-release form, or 16–24 mg once daily in extended-release form). The starting dose is 8 mg/day, titrated upward every 4 weeks. • Bioavailability: Oral bioavailability is approximately 88–100% with rapid and nearly complete gastrointestinal absorption. Time to peak plasma concentration (Tmax) is ~1 hour for immediate-release and ~4.5–5 hours for extended-release formulations. Plasma protein binding is approximately 18%, indicating high free-fraction availability. Volume of distribution is ~175 L. • [Metabolism](/ingredients/condition/weight-management): Primarily hepatized via CYP2D6 and CYP3A4 cytochrome P450 enzymes. Major metabolites include O-desmethylgalanthamine, galanthamine-N-oxide, and epigalanthamine — none with clinically significant AChE inhibition. Terminal elimination half-life is approximately 7–8 hours. Approximately 20–25% is excreted unchanged in urine. CYP2D6 poor metabolizers exhibit ~35% higher AUC. • Additional bioactive properties: Exhibits weak [antioxidant activity](/ingredients/condition/antioxidant) (ORAC data limited); demonstrates anti-inflammatory effects via α7 nAChR-mediated suppression of TNF-α and IL-6 release (cholinergic anti-[inflammatory pathway](/ingredients/condition/inflammation) activation); no significant caloric, vitamin, mineral, or fiber content as it is administered as a pure pharmaceutical compound (typically as galanthamine hydrobromide salt, MW 368.27 g/mol). • No macronutrient content: 0 g protein, 0 g fat, 0 g carbohydrate, 0 g fiber, 0 kcal per dose. Contains no vitamins or minerals in therapeutic formulation beyond inactive excipients.

## Dosage & Preparation

Clinical studies used immediate-release oral tablets of galanthamine hydrobromide, escalated over 4-8 weeks to maintenance doses of 16-24 mg/day (typically 8 mg twice daily). Maximum studied dose is 32 mg/day, though this showed higher gastrointestinal side effects. Only pharmaceutical-grade standardized forms (>98% purity) have been clinically tested. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

The most common adverse effects of galanthamine are dose-dependent gastrointestinal symptoms including nausea (up to 30% of users), vomiting, diarrhea, and anorexia, which are minimized by titrating slowly from 8 mg/day to the target dose of 16–24 mg/day over several weeks. It carries a risk of bradycardia and should be used with caution in patients with sick sinus syndrome, cardiac conduction disorders, or those taking beta-blockers, digoxin, or other drugs that slow heart rate. Galanthamine is contraindicated with other cholinesterase inhibitors (e.g., donepezil, rivastigmine) due to additive cholinergic toxicity risk, and concurrent use of strong CYP2D6 or CYP3A4 inhibitors such as paroxetine, ketoconazole, or erythromycin can significantly raise galanthamine plasma levels. It is classified FDA Pregnancy Category B based on animal data; safety in human pregnancy and lactation has not been established and its use is generally avoided in these populations.

## Scientific Research

Multiple large-scale randomized controlled trials demonstrate galanthamine's efficacy, including studies with 636 patients (PMID 10881250), 978 patients (PMID 10881251), and a landmark 2-year trial with 2,045 patients (PMC3937252) showing 34% less [cognitive](/ingredients/condition/cognitive) decline. A 2024 Cochrane meta-analysis (PMID 39498781) confirmed that 16-24 mg/day doses consistently slow cognitive decline versus placebo.

## Historical & Cultural Context

In Bulgarian folk medicine since the 1950s, galanthamine-rich Leucojum aestivum bulb extracts were used to treat neuralgia, neuritis, and myasthenia gravis. The compound was first isolated in 1959 by P.N. Doytchinova and has been in Eastern European pharmacopeias since the 1960s for neurological conditions.

## Synergistic Combinations

Alpha-GPC, Huperzine A, Lion's Mane, Ginkgo biloba, Phosphatidylserine

## Frequently Asked Questions

### What is galanthamine and how does it work for Alzheimer's disease?

Galanthamine is a naturally occurring alkaloid extracted from snowdrop and daffodil bulbs that works as an acetylcholinesterase inhibitor, preventing the breakdown of acetylcholine in the brain. Clinical trials have shown it improves cognitive function in mild-to-moderate Alzheimer's disease by 3-4 points on the ADAS-cog scale and reduces cognitive decline progression by 34% over 2 years compared to placebo.

### What plants contain galanthamine naturally?

Galanthamine is found in bulbs of Amaryllidaceae family plants, including snowdrop (Galanthus woronowii), common daffodil (Narcissus pseudonarcissus), and snowflake (Leucojum aestivum). The compound is extracted using ethanol or methanol solvents, followed by chromatographic purification to obtain pharmaceutical-grade galanthamine.

### Is galanthamine FDA approved for dementia treatment?

Yes, galanthamine is FDA-approved for treating mild-to-moderate Alzheimer's disease under brand names like Razadyne. Clinical evidence from multiple randomized controlled trials involving 636-2045 patients demonstrates its efficacy in improving cognitive function and reducing activities of daily living decline by 24% in 2-year studies.

### What are the side effects of galanthamine?

Common side effects of galanthamine include nausea, vomiting, diarrhea, and loss of appetite, particularly during initial treatment phases. As an acetylcholinesterase inhibitor, galanthamine can also cause dizziness, headache, and fatigue, with gastrointestinal effects being the most frequently reported adverse reactions in clinical trials.

### How long has galanthamine been used medicinally?

Galanthamine has been used in Bulgarian folk medicine since the 1950s, where Leucojum aestivum bulb extracts treated neuralgia, neuritis, and myasthenia gravis. The pure compound was first isolated in 1959 by P.N. Doytchinova and has been included in Eastern European pharmacopeias since the 1960s for neurological conditions.

### What is the recommended dosage of galanthamine for cognitive decline?

Standard galanthamine dosing for Alzheimer's disease typically ranges from 8–12 mg daily, taken in divided doses, though treatment usually begins at lower doses (4 mg) and is gradually increased to minimize side effects. Dosage adjustments may be necessary based on individual tolerance and hepatic or renal function. Always follow prescribing guidelines provided by a healthcare provider, as galanthamine is a prescription medication in most countries.

### Is galanthamine safe for elderly patients with kidney or liver problems?

Galanthamine requires dose adjustment or careful monitoring in patients with moderate-to-severe renal or hepatic impairment due to reduced drug clearance, which can increase side effects and toxicity risk. Elderly patients with kidney or liver disease should be evaluated by a physician to determine appropriate dosing and whether galanthamine is suitable for their individual health status. Regular monitoring of liver and kidney function tests is recommended during galanthamine therapy.

### Does galanthamine interact with common medications like antidepressants or blood pressure drugs?

Galanthamine can interact with medications that affect acetylcholine levels, including certain antidepressants, and may enhance effects of anesthetics or anticholinergic agents; it should be used cautiously with NSAIDs due to increased GI bleeding risk. Concurrent use with beta-blockers or calcium channel blockers may cause additive effects on heart rate and blood pressure. Patients on multiple medications should inform their physician about galanthamine use to avoid potentially serious drug interactions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*